查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1759485

青蒿琥酯注射劑的全球市場:純度·用途·終端用戶·通路·各地區 (～2032年)

Global Artesunate Injection Market Research Report Information by Purity, by Application, by End User, by Distribution Channel, by Region Industry Forecast till 2032
出版日期: | 出版商: Market Research Future | 英文 107 Pages | 訂單完成後即時交付

價格

預計全球青蒿琥酯注射劑市場規模將從 2023 年的約 8,500 萬美元增長至 2024-2032 年預測期內的 0.9% 的中等複合年增長率。

主要成長動力包括瘧疾盛行率的上升、對速效注射療法的日益青睞以及生產和分銷系統的進步。此外，透過全球宣傳活動提高認識和早期診斷也對提高治療率產生了積極影響。

然而，一些阻礙因素阻礙了市場潛力的發揮。高昂的生產和治療成本、部分地區供應不穩定以及嚴格的監管審批程序都是阻礙因素。此外，複雜的智慧財產權問題以及來自其他抗瘧藥物的競爭也對市場成長帶來壓力。

儘管存在這些阻礙因素，但仍存在成長機會。例如，遠距醫療平台的普及正在擴大瘧疾流行地區偏遠地區診斷和治療的可近性。此外，加強公私合作正在增加對瘧疾相關醫療解決方案的資金投入。此外，區域製造基地的發展有助於穩定供應鏈，醫療基礎設施的整體發展也有助於提高青蒿琥酯注射的可近性。

區域展望

隨著全球健康意識的增強，北美對青蒿琥酯注射的需求正在增長。這主要是由於前往瘧疾流行地區的旅行者人數增加。儘管加拿大和美國沒有地方性瘧疾感染，但海外輸入病例呈現增加趨勢，因此需要獲得青蒿琥酯這種快速有效的治療方法，以防止病情惡化。

在歐洲，青蒿琥酯已被歐洲藥品管理局 (EMA) 認可為治療重症瘧疾的高效藥物，並已被許多國家納入國家治療指南。然而，監管複雜性和成本方面的課題仍然存在，限制了該藥物在該地區更廣泛的應用。

在亞太地區，隨著世界衛生組織 (WHO) 推薦青蒿琥酯作為重症瘧疾的一線治療藥物，青蒿琥酯的推廣應用正在不斷擴大。根據這項建議，青蒿琥酯已被正式納入瘧疾流行國家的官方醫療方案，其在臨床實踐中的應用也正在不斷擴大。

在南美洲，秘魯、巴西和哥倫比亞等亞馬遜國家瘧疾感染率居高不下，這使得青蒿琥酯成為國家瘧疾控制計畫的重要組成部分，尤其是在重症瘧疾患者中。

中非國家，尤其是剛果民主共和國，瘧疾發生率極高，因此青蒿琥酯成為重要的第一線治療藥物。

本報告提供全球青蒿琥酯注射劑的市場調查，彙整市場定義和概要，市場成長的各種影響因素分析，市場規模的轉變·預測，各種區分·地區/各主要國家的明細，競爭環境，主要企業簡介等資訊。

目錄

第1章 摘要整理

第2章 市場概要

第3章 調查手法

第4章 市場動態

  • 促進因素
    • 瘧疾盛行率上升
    • 注射劑治療需求增加
    • 製造和分銷技術的進步
    • 提高認識和教育水平
  • 阻礙因素
    • 注射用青蒿琥酯成本高
    • 注射用青蒿琥酯成本高
    • 監理課題與漫長的審批流程
    • 智慧財產權和專利問題
    • 與其他抗瘧藥的競爭藥物
  • 機會
    • 遠距醫療：擴大醫療服務，提高偏遠地區診斷和治療的可近性
    • 增加對瘧疾研究的公私合作資金
    • 開發聯合療法，提高治療效果
    • 區域製造中心的出現，增強供應鏈
    • 對整體醫療保健產業的影響
    • 對全球青蒿琥酯注射市場的影響
    • 對青蒿琥酯注射市場供應鏈的影響
    • 對青蒿琥酯注射市場需求的影響
    • 對青蒿琥酯注射劑市場價格的影響

第5章 市場要素分析

  • 供應鏈分析
  • 波特的五力分析

第6章 全球青蒿琥酯注射劑市場:純度

  • 青蒿琥酯0.99
  • 青蒿琥酯0.98

第7章 全球青蒿琥酯注射劑市場:各用途

  • 瘧疾
  • 重病瘧疾
  • 腦瘧疾
  • 併發症的沒有的瘧疾

第8章 全球青蒿琥酯注射劑市場:各終端用戶

  • 醫院
  • 診所
  • 藥局
  • 政府機關
  • 非官方機構

第9章 全球青蒿琥酯注射劑市場:各流通管道

  • 直銷
  • 銷售商及批發商
  • 零售藥局
  • 線上銷售

第10章 全球青蒿琥酯注射劑市場:各地區

  • 概要
  • 北美
  • 歐洲
  • 亞太地區
  • 南美
  • 中東·非洲

第11章 競爭情形

  • 市場佔有率分析
  • 競爭儀表板
  • 主要的展開·成長策略

第12章 企業簡介

  • AMIVAS
  • ADVACARE PHARMA
  • ZYDUS CADILA
  • INTAS PHARMACEUTICAL
  • SYSTACARE REMEDIES
  • LEXICARE PHARMA
  • CIPLA
  • GUILIN PHARMA
  • IPCA LABORATORIES
  • WATRAN PHARMACEUTICALS PVT. LTD
Product Code: MRFR/HC/38057-HCR

Global Artesunate Injection Market Research Report Information by Purity (Artesunate 0.99, Artesunate 0.98), by Application (Malaria, Severe Malaria, Cerebral Malaria, Uncomplicated Malaria, Other Applications), by End User (Hospitals, Clinics, Pharmacies, Government Institutions, Non-Governmental Organizations), by Distribution Channel (Direct Sales, Distributors and Wholesalers, Retail Pharmacies, and Online Sales), by Region (North America, Europe, APAC, South America, MEA) Industry Forecast till 2032

Market Analysis

In 2023, the global artesunate injection market reached a valuation of approximately USD 85 million. From 2024 to 2032, the market is anticipated to grow at a modest compound annual growth rate (CAGR) of 0.9%. Key growth factors include the increasing burden of malaria, the rising preference for injectable therapies that offer rapid action, and advancements in manufacturing and distribution systems. In addition, improved awareness and early diagnosis due to global education initiatives have positively influenced treatment rates.

However, several limitations hinder the market's potential. High production and treatment costs, inconsistent availability in various regions, and stringent regulatory approval processes create roadblocks. Complex intellectual property issues and competition from alternative antimalarial drugs also add pressure to market growth.

Despite these restraints, opportunities exist. The rise of telehealth platforms is helping expand access to diagnosis and treatment in remote, malaria-affected regions. Furthermore, increased collaboration between public and private sectors is resulting in greater funding for malaria-related healthcare solutions. The development of regional manufacturing centers is improving supply chain stability, and general progress in healthcare infrastructure is facilitating better access to artesunate injections. Together, these trends are shaping market dynamics and influencing future pricing, accessibility, and overall demand for artesunate therapies.

Industry Segmentation

Depending on the purity type, the global artesunate injection market is divided into Artesunate 0.99 and Artesunate 0.98.

The global artesunate injection market is divided into end user industry, such as hospitals, clinics, pharmacies, government institutions, non-governmental organizations.

The application type of the global market comprises malaria, severe malaria, cerebral malaria, uncomplicated malaria, other applications.

Based on the distribution channel, the global market has been categorized into direct sales, distributors and wholesalers, retail pharmacies, and online sales.

In terms of regions, the global market comprises, Middle East & Africa, Europe, North America, South America, and Asia Pacific.

Regional Perspectives

In North America, increasing global health awareness has contributed to rising demand for artesunate injections, primarily due to the growing number of travelers visiting malaria-endemic countries. Although malaria is not endemic in Canada or the United States, the region has witnessed a rise in imported cases, necessitating access to rapid and effective treatments like artesunate to prevent severe complications.

In Europe, artesunate has gained recognition from the European Medicines Agency (EMA) as a highly effective treatment for severe malaria. Consequently, many countries have incorporated it into their national treatment guidelines. However, regulatory complexities and cost-related challenges still limit its broader use across the continent.

The Asia-Pacific region has seen expanded adoption of artesunate, largely driven by the World Health Organization's (WHO) recommendation endorsing it as the first-line treatment for severe malaria. This has led to its inclusion in official healthcare protocols throughout malaria-prone nations in the region.

In South America, nations within the Amazon Basin, including Peru, Brazil, and Colombia, continue to experience high rates of malaria transmission. Artesunate plays a crucial role in national malaria response programs, especially for severe infections.

Central African countries like the Democratic Republic of the Congo (DRC) face a heavy malaria burden, where artesunate remains an essential component of frontline treatment.

Major Competitors

Cipla, Guilin Pharma, IPCA Laboratories, AMIVAS, Advacare Pharma, Zydus Cadila, Intas Pharmaceutical, Systacare Remedies, Lexicare Pharma, Watran Pharmaceuticals Pvt. Ltd. are the leading companies in the Global Artesunate Injection Market Research.

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

2 MARKET INTRODUCTION

  • 2.1 DEFINITION
  • 2.2 SCOPE OF THE STUDY
  • 2.3 RESEARCH OBJECTIVE
  • 2.4 MARKET STRUCTURE

3 RESEARCH METHODOLOGY

  • 3.1 OVERVIEW
  • 3.2 DATA FLOW
    • 3.2.1 DATA MINING PROCESS
  • 3.3 PURCHASED DATABASE:
  • 3.4 SECONDARY SOURCES:
    • 3.4.1 SECONDARY RESEARCH DATA FLOW:
  • 3.5 PRIMARY RESEARCH:
    • 3.5.1 PRIMARY RESEARCH DATA FLOW:
    • 3.5.2 PRIMARY RESEARCH: NUMBER OF INTERVIEWS CONDUCTED
    • 3.5.3 PRIMARY RESEARCH: REGIONAL COVERAGE
  • 3.6 APPROACHES FOR MARKET END USER ESTIMATION:
    • 3.6.1 REVENUE ANALYSIS APPROACH
    • 3.6.2 DATA FORECASTING
    • 3.6.3 DATA FORECASTING TECHNIQUE
  • 3.7 DATA MODELING
    • 3.7.1 MICROECONOMIC FACTOR ANALYSIS:
    • 3.7.2 DATA MODELING:
  • 3.8 TEAMS AND ANALYST CONTRIBUTION

4 MARKET DYNAMICS

  • 4.1 INTRODUCTION
  • 4.2 DRIVERS
    • 4.2.1 INCREASING PREVALENCE OF MALARIA
    • 4.2.2 GROWING DEMAND FOR INJECTABLE TREATMENTS
    • 4.2.3 ADVANCEMENTS IN MANUFACTURING AND DISTRIBUTION
    • 4.2.4 GROWING AWARENESS AND EDUCATION
  • 4.3 RESTRAINTS
    • 4.3.1 HIGH COST OF ARTESUNATE INJECTIONS
    • 4.3.2 LIMITED AVAILABILITY IN CERTAIN REGIONS
    • 4.3.3 REGULATORY CHALLENGES AND LENGTHY APPROVAL PROCESSES
    • 4.3.4 INTELLECTUAL PROPERTY AND PATENT ISSUES
    • 4.3.5 COMPETING ANTIMALARIAL THERAPIES
  • 4.4 OPPORTUNITY
    • 4.4.1 EXPANSION OF TELEHEALTH SERVICES FOR REMOTE DIAGNOSIS AND TREATMENT
    • 4.4.2 INCREASED PUBLIC-PRIVATE PARTNERSHIPS FOR FUNDING MALARIA RESEARCH
    • 4.4.3 DEVELOPMENT OF COMBINATION THERAPIES TO ENHANCE TREATMENT EFFICACY
    • 4.4.4 EMERGENCE OF REGIONAL MANUFACTURING HUBS TO BOOST SUPPLY CHAIN RESILIENCE
    • 4.4.5 IMPACT ON OVERALL HEALTHCARE SECTOR
    • 4.4.6 IMPACT ON GLOBAL ARTESUNATE INJECTION MARKET
    • 4.4.7 IMPACT ON THE SUPPLY CHAIN OF THE ARTESUNATE INJECTION MARKET
    • 4.4.8 IMPACT ON MARKET DEMAND OF ARTESUNATE INJECTION MARKET
    • 4.4.9 IMPACT ON PRICING OF ARTESUNATE INJECTION MARKET

5 MARKET FACTOR ANALYSIS

  • 5.1 SUPPLY CHAIN ANALYSIS
    • 5.1.1 RAW MATERIAL SUPPLIERS
    • 5.1.2 MANUFACTURING
    • 5.1.3 DISTRIBUTION AND LOGISTICS
    • 5.1.4 RETAIL AND CONSUMPTION
  • 5.2 PORTER'S FIVE FORCES MODEL
    • 5.2.1 BARGAINING POWER OF SUPPLIERS
    • 5.2.2 BARGAINING POWER OF BUYERS
    • 5.2.3 THREAT OF NEW ENTRANTS
    • 5.2.4 THREAT OF SUBSTITUTES
    • 5.2.5 INTENSITY OF RIVALRY

6 GLOBAL ARTESUNATE INJECTION MARKET, BY PURITY

  • 6.1 INTRODUCTION
  • 6.2 ARTESUNATE 0.99
  • 6.3 ARTESUNATE 0.98

7 GLOBAL ARTESUNATE INJECTION MARKET, BY APPLICATION

  • 7.1 INTRODUCTION
    • 7.1.1 MALARIA
    • 7.1.2 SEVERE MALARIA
    • 7.1.3 CEREBRAL MALARIA
    • 7.1.4 UNCOMPLICATED MALARIA

8 GLOBAL ARTESUNATE INJECTION MARKET, BY END USER

  • 8.1 INTRODUCTION
    • 8.1.1 HOSPITALS
    • 8.1.2 CLINICS
    • 8.1.3 PHARMACIES
    • 8.1.4 GOVERNMENT INSTITUTIONS
    • 8.1.5 NON-GOVERNMENTAL ORGANIZATIONS

9 GLOBAL ARTESUNATE INJECTION MARKET, BY DISTRIBUTION CHANNEL

  • 9.1 INTRODUCTION
    • 9.1.1 DIRECT SALES
    • 9.1.2 DISTRIBUTORS AND WHOLESALERS
    • 9.1.3 RETAIL PHARMACIES
    • 9.1.4 ONLINE SALES

10 GLOBAL ARTESUNATE INJECTION MARKET, BY REGION

  • 10.1 OVERVIEW
  • 10.2 NORTH AMERICA
  • 10.3 EUROPE
  • 10.4 ASIA PACIFIC
  • 10.5 SOUTH AMERICA
  • 10.6 MIDDLE EAST & AFRICA

11 COMPETITIVE LANDSCAPE

  • 11.1 INTRODUCTION
  • 11.2 MARKET SHARE ANALYSIS, 2023
  • 11.3 COMPETITOR DASHBOARD
  • 11.4 KEY DEVELOPMENTS & GROWTH STRATEGIES
    • 11.4.1 LAUNCH DEVELOPMENTS

12 COMPANY PROFILES

  • 12.1 AMIVAS
    • 12.1.1 COMPANY OVERVIEW
    • 12.1.2 TYPES OFFERED
    • 12.1.3 SWOT ANALYSIS
    • 12.1.4 KEY STRATEGY
  • 12.2 ADVACARE PHARMA
    • 12.2.1 COMPANY OVERVIEW
    • 12.2.2 TYPES OFFERED
    • 12.2.3 SWOT ANALYSIS
    • 12.2.4 KEY STRATEGY
  • 12.3 ZYDUS CADILA
    • 12.3.1 COMPANY OVERVIEW
    • 12.3.2 TYPES OFFERED
    • 12.3.3 SWOT ANALYSIS
    • 12.3.4 KEY STRATEGY
  • 12.4 INTAS PHARMACEUTICAL
    • 12.4.1 COMPANY OVERVIEW
    • 12.4.2 TYPES OFFERED
    • 12.4.3 SWOT ANALYSIS
    • 12.4.4 KEY STRATEGY
  • 12.5 SYSTACARE REMEDIES
    • 12.5.1 COMPANY OVERVIEW
    • 12.5.2 TYPES OFFERED
    • 12.5.3 SWOT ANALYSIS
    • 12.5.4 KEY STRATEGY
  • 12.6 LEXICARE PHARMA
    • 12.6.1 COMPANY OVERVIEW
    • 12.6.2 TYPES OFFERED
    • 12.6.3 SWOT ANALYSIS
  • 12.7 CIPLA
    • 12.7.1 COMPANY OVERVIEW
    • 12.7.2 TYPES OFFERED
    • 12.7.3 SWOT ANALYSIS
    • 12.7.4 KEY STRATEGY
  • 12.8 GUILIN PHARMA
    • 12.8.1 COMPANY OVERVIEW
    • 12.8.2 TYPES OFFERED
    • 12.8.3 SWOT ANALYSIS
  • 12.9 IPCA LABORATORIES
    • 12.9.1 COMPANY OVERVIEW
    • 12.9.2 TYPES OFFERED
    • 12.9.3 SWOT ANALYSIS
  • 12.10 WATRAN PHARMACEUTICALS PVT. LTD
    • 12.10.1 COMPANY OVERVIEW
    • 12.10.2 TYPES OFFERED
    • 12.10.3 SWOT ANALYSIS

LIST OF TABLES

  • TABLE 1 GLOBAL ARTESUNATE INJECTION MARKET, BY PURITY, 2018-2032 (USD)
  • TABLE 2 GLOBAL ARTESUNATE INJECTION MARKET, BY APPLICATION, 2018-2032 (USD)
  • TABLE 3 GLOBAL ARTESUNATE INJECTION MARKET, BY END USER, 2018-2032 (USD)
  • TABLE 4 GLOBAL ARTESUNATE INJECTION MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD)
  • TABLE 5 GLOBAL ARTESUNATE INJECTION MARKET, BY REGION, 2018-2032 (USD)
  • TABLE 6 NORTH AMERICA: ARTESUNATE INJECTION MARKET, BY COUNTRY, 2018-2032 (USD)
  • TABLE 7 NORTH AMERICA ARTESUNATE INJECTION MARKET, BY PURITY, 2018-2032 (USD)
  • TABLE 8 NORTH AMERICA ARTESUNATE INJECTION MARKET, BY APPLICATION, 2018-2032 (USD)
  • TABLE 9 NORTH AMERICA ARTESUNATE INJECTION MARKET, BY END USER, 2018-2032 (USD)
  • TABLE 10 NORTH AMERICA ARTESUNATE INJECTION MARKET, DISTRIBUTION CHANNEL, 2018-2032 (USD)
  • TABLE 11 US ARTESUNATE INJECTION MARKET, BY PURITY, 2018-2032 (USD )
  • TABLE 12 US: ARTESUNATE INJECTION MARKET, BY APPLICATION, 2018-2032 (USD)
  • TABLE 13 US ARTESUNATE INJECTION MARKET, BY END USER, 2018-2032 (USD)
  • TABLE 14 US ARTESUNATE INJECTION MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD)
  • TABLE 15 CANADA ARTESUNATE INJECTION MARKET, BY PURITY, 2018-2032 (USD )
  • TABLE 16 CANADA: ARTESUNATE INJECTION MARKET, BY APPLICATION, 2018-2032 (USD )
  • TABLE 17 CANADA ARTESUNATE INJECTION MARKET, BY END USER, 2018-2032 (USD )
  • TABLE 18 CANADA ARTESUNATE INJECTION MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD )
  • TABLE 19 EUROPE: ARTESUNATE INJECTION MARKET, BY COUNTRY, 2018-2032 (USD )
  • TABLE 20 EUROPE ARTESUNATE INJECTION MARKET, BY PURITY, 2018-2032 (USD )
  • TABLE 21 EUROPE: ARTESUNATE INJECTION MARKET, BY APPLICATION, 2018-2032 (USD )
  • TABLE 22 EUROPE ARTESUNATE INJECTION MARKET, BY END USER, 2018-2032 (USD )
  • TABLE 23 EUROPE ARTESUNATE INJECTION MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD )
  • TABLE 24 ASIA PACIFIC: ARTESUNATE INJECTION MARKET, BY COUNTRY, 2018-2032 (USD )
  • TABLE 25 ASIA PACIFIC ARTESUNATE INJECTION MARKET, BY PURITY, 2018-2032 (USD )
  • TABLE 26 ASIA PACIFIC: ARTESUNATE INJECTION MARKET, BY APPLICATION, 2018-2032 (USD )
  • TABLE 27 ASIA PACIFIC ARTESUNATE INJECTION MARKET, BY END USER, 2018-2032 (USD )
  • TABLE 28 ASIA PACIFIC ARTESUNATE INJECTION MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD )
  • TABLE 29 SOUTH AMERICA: ARTESUNATE INJECTION MARKET, BY COUNTRY, 2018-2032 (USD )
  • TABLE 30 SOUTH AMERICA ARTESUNATE INJECTION MARKET, BY PURITY, 2018-2032 (USD )
  • TABLE 31 SOUTH AMERICA: ARTESUNATE INJECTION MARKET, BY APPLICATION, 2018-2032 (USD )
  • TABLE 32 SOUTH AMERICA ARTESUNATE INJECTION MARKET, BY END USER, 2018-2032 (USD )
  • TABLE 33 SOUTH AMERICA ARTESUNATE INJECTION MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD )
  • TABLE 34 MIDDLE EAST & AFRICA: ARTESUNATE INJECTION MARKET, BY COUNTRY, 2018-2032 (USD )
  • TABLE 35 MIDDLE EAST & AFRICA ARTESUNATE INJECTION MARKET, BY PURITY, 2018-2032 (USD )
  • TABLE 36 MIDDLE EAST & AFRICA: ARTESUNATE INJECTION MARKET, BY APPLICATION, 2018-2032 (USD )
  • TABLE 37 MIDDLE EAST & AFRICA ARTESUNATE INJECTION MARKET, BY END USER, 2018-2032 (USD )
  • TABLE 38 MIDDLE EAST & AFRICA ARTESUNATE INJECTION MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD )
  • TABLE 39 LAUNCH DEVELOPMENTS
  • TABLE 40 AMIVAS: PRODUCT OFFERED
  • TABLE 41 ADVACARE PHARMA: TYPES OFFERED
  • TABLE 42 ZYDUS CADILA: TYPES OFFERED
  • TABLE 43 INTAS PHARMACEUTICAL: TYPES OFFERED
  • TABLE 44 SYSTACARE REMEDIES: TYPES OFFERED
  • TABLE 45 LEXICARE PHARMA: TYPES OFFERED
  • TABLE 46 CIPLA: TYPES OFFERED
  • TABLE 47 GUILIN PHARMA: TYPES OFFERED
  • TABLE 48 IPCA LABORATORIES: TYPES OFFERED
  • TABLE 49 WATRAN PHARMACEUTICALS PVT. LTD: TYPES OFFERED

LIST OF FIGURES

  • FIGURE 1 GLOBAL ARTESUNATE INJECTION MARKET: STRUCTURE
  • FIGURE 2 GLOBAL ARTESUNATE INJECTION MARKET: MARKET GROWTH FACTOR ANALYSIS (2023-2032)
  • FIGURE 3 DRIVER IMPACT ANALYSIS (2024-2032)
  • FIGURE 4 RESTRAINT IMPACT ANALYSIS (2023-2032)
  • FIGURE 5 SUPPLY CHAIN ANALYSIS: GLOBAL ARTESUNATE INJECTION MARKET
  • FIGURE 7 PORTER'S FIVE FORCES MODEL: GLOBAL ARTESUNATE INJECTION MARKET
  • FIGURE 8 GLOBAL ARTESUNATE INJECTION MARKET, BY PURITY, SEGMENT ATTRACTIVENESS ANALYSIS
  • FIGURE 9 GLOBAL ARTESUNATE INJECTION MARKET, BY PURITY, 2023 (% SHARE)
  • FIGURE 10 GLOBAL ARTESUNATE INJECTION MARKET, BY APPLICATION, SEGMENT ATTRACTIVENESS ANALYSIS
  • FIGURE 11 GLOBAL ARTESUNATE INJECTION MARKET, BY APPLICATION, 2023 (% SHARE)
  • FIGURE 12 GLOBAL ARTESUNATE INJECTION MARKET, BY END USER, SEGMENT ATTRACTIVENESS ANALYSIS
  • FIGURE 13 GLOBAL ARTESUNATE INJECTION MARKET, BY END USER, 2023 (% SHARE)
  • FIGURE 14 GLOBAL ARTESUNATE INJECTION MARKET, BY DISTRIBUTION CHANNEL, SEGMENT ATTRACTIVENESS ANALYSIS
  • FIGURE 15 GLOBAL ARTESUNATE INJECTION MARKET, BY DISTRIBUTION CHANNEL, 2023 (% SHARE)
  • FIGURE 16 GLOBAL ARTESUNATE INJECTION MARKET, BY REGION, 2023 (% SHARE)
  • FIGURE 17 NORTH AMERICAN MARKET: SWOT ANALYSIS
  • FIGURE 18 NORTH AMERICA: ARTESUNATE INJECTION MARKET SHARE, BY COUNTRY, 2023 (% SHARE)
  • FIGURE 19 EUROPE MARKET: SWOT ANALYSIS
  • FIGURE 20 EUROPE: ARTESUNATE INJECTION MARKET SHARE, BY COUNTRY, 2023 (% SHARE)
  • FIGURE 21 ASIA PACIFIC MARKET: SWOT ANALYSIS
  • FIGURE 22 ASIA PACIFIC: ARTESUNATE INJECTION MARKET SHARE, BY COUNTRY, 2023 (% SHARE)
  • FIGURE 23 SOUTH AMERICA MARKET: SWOT ANALYSIS
  • FIGURE 24 SOUTH AMERICA: ARTESUNATE INJECTION MARKET SHARE, BY COUNTRY, 2023 (% SHARE)
  • FIGURE 25 MIDDLE EAST & AFRICA MARKET: SWOT ANALYSIS
  • FIGURE 26 MIDDLE EAST & AFRICA: ARTESUNATE INJECTION MARKET SHARE, BY COUNTRY, 2023 (% SHARE)
  • FIGURE 27 GLOBAL ARTESUNATE INJECTION PLAYERS: COMPETITIVE ANALSIS, 2023
  • FIGURE 28 COMPETITOR DASHBOARD: GLOBAL ARTESUNATE INJECTION
  • FIGURE 29 AMIVAS: SWOT ANALYSIS
  • FIGURE 30 ADVACARE PHARMA: SWOT ANALYSIS
  • FIGURE 31 ZYDUS CADILA: SWOT ANALYSIS
  • FIGURE 32 INTAS PHARMACEUTICAL: SWOT ANALYSIS
  • FIGURE 33 SYSTACARE REMEDIES: SWOT ANALYSIS
  • FIGURE 34 LEXICARE PHARMA: SWOT ANALYSIS
  • FIGURE 35 CIPLA: SWOT ANALYSIS
  • FIGURE 36 GUILIN PHARMA: SWOT ANALYSIS
  • FIGURE 37 IPCA LABORATORIES: SWOT ANALYSIS
  • FIGURE 38 WATRAN PHARMACEUTICALS PVT. LTD: SWOT ANALYSIS